Direct estrogen receptor (ER) / HER family crosstalk mediating sensitivity to lumretuzumab and pertuzumab in ER+ breast cancer

• Denis Collins ,

  * E-mail: denis.collins@dcu.ie (DC); martin.weisser@roche.com (MW)

  Affiliation National Institute for Cellular Biotechnology, Dublin City University, Dublin, Ireland

  ⨯
• Wolfgang Jacob,

  Affiliation Roche Innovation Center Munich, Penzberg, Germany

  ⨯
• Juan Miguel Cejalvo,

  Affiliation Department of Medical Oncology, Institute of Health Research INCLIVA, University of Valencia, Valencia, Spain

  ⨯
• Maurizio Ceppi,

  Affiliation Roche Innovation Center Munich, Penzberg, Germany

  ⨯
• Ian James,

  Affiliation A4P Consulting Ltd, Sandwich, United Kingdom

  ⨯
• Max Hasmann,

  Affiliation Roche Innovation Center Munich, Penzberg, Germany

  ⨯
• John Crown,

  Affiliations National Institute for Cellular Biotechnology, Dublin City University, Dublin, Ireland, Department of Medical Oncology, St. Vincent's University Hospital, Dublin, Ireland

  ⨯
• Andrés Cervantes,

  Affiliation Department of Medical Oncology, Institute of Health Research INCLIVA, University of Valencia, Valencia, Spain

  ⨯
• Martin Weisser ,

  * E-mail: denis.collins@dcu.ie (DC); martin.weisser@roche.com (MW)

  Affiliation Roche Innovation Center Munich, Penzberg, Germany

  ⨯
• Birgit Bossenmaier

  Affiliation Roche Innovation Center Munich, Penzberg, Germany

  http://orcid.org/0000-0002-3313-6161

  ⨯